Related Experiment Video

Updated: Jun 18, 2026

Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model
08:06

Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model

Published on: November 26, 2010

Inhibition of tumor metastasis: functional immune modulation of the CUB domain containing protein 1

Keisuke Fukuchi1, Sebastian C J Steiniger, Elena Deryugina

  • 1The Skaggs Institute for Chemical Biology, Department of Chemistry, The Scripps Research Institute, La Jolla, California 92037, USA.

Molecular Pharmaceutics
|November 18, 2009
PubMed

Insights

Researchers developed function-blocking antibodies against CUB domain containing protein 1 (CDCP1), a tumor-associated protein. These antibodies effectively inhibited cancer metastasis and reduced tumor cell growth, showing therapeutic potential for cancer immunotherapy.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Malignant diseases present significant challenges in healthcare.
  • Targeted therapies focus on tumor-specific proteins to minimize damage to normal tissues.
  • CUB domain containing protein 1 (CDCP1) is upregulated in tumors, making it a target for cancer immunotherapy.

Purpose of the Study:

  • To generate function-blocking human antibodies against CDCP1.
  • To evaluate the therapeutic potential of these antibodies in preclinical cancer models.
  • To investigate the role of CDCP1 in cancer progression and metastasis.

Main Methods:

  • Human scFv phage display libraries were used to isolate anti-CDCP1 antibodies.
  • Subtractive panning protocols were employed using CDCP1-expressing cancer cells and purified CDCP1 protein.
  • Antibody efficacy was tested in chick embryo and mouse models for metastasis inhibition.
  • Soft agar assays assessed anchorage-independent cell growth.
  • Toxin-conjugated antibody complexes were used to evaluate antibody internalization and tumor cell killing.

Main Results:

  • A function-blocking antibody, C20Fc, was generated against CDCP1.
  • C20Fc significantly inhibited experimental metastasis of human carcinoma cells in vivo.
  • The antibody reduced colony formation in soft agar assays, indicating a reduction in anchorage-independent growth.
  • C20Fc mediated toxin delivery, confirming antibody internalization and specific killing of CDCP1-positive tumor cells.

Conclusions:

  • CDCP1 plays a functional role in human cancer progression.
  • Function-blocking anti-CDCP1 antibodies demonstrate significant therapeutic potential.
  • These antibodies can target both primary and metastatic carcinoma cells, offering a novel immunotherapy strategy.

More Related Videos

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...